Spondyloarthritis & psoriatic arthritis
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Authors' conclusion
Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi) in routine care, 15 European registries
- Participants
- 19,498 patients15 European registries
- Exposure
- Ankylosing spondylitis (AS) vs nr-axSpA; first vs second and third TNFi
- ASn = 3,281
- nr-axSpAn = 993reference
- Outcome
- PRO remission rates (≤ 20 mm for pain, fatigue, PtGA, BASDAI, BASFI; ≤ 0.5 for HAQ) and changes in patient-reported outcomes (PROs)
- Follow-up
- 6, 12, and 24 months
Methodological detailspooled analysis of European registries, multinational, 15 registries, LUNDEX-adjusted remission rates
- Pooled analysis of European registries
- Multinational
- 15 registries
- LUNDEX-adjusted remission rates
Main finding
As reported in the abstract
LUNDEX-adjusted PRO remission rates (pain/fatigue/PtGA/BASDAI/BASFI/HAQ) · 6 months
LUNDEX-adjusted PRO remission rates (pain/fatigue/PtGA/BASDAI/BASFI/HAQ) · 6 months AS 39%/30%/38%/34%/35%/48% · nr-axSpA 30%/21%/26%/24%/33%/47%
Pain
Fatigue
PtGA
BASDAI
BASFI
HAQ
Observational data: associations, not effects.
Further findings
Median PRO scores at baseline/6/12/24 months, first TNFi, pooled data (patients on treatment)
- Pain (mm)
- 65/25/20/20
- Fatigue (mm)
- 68/32/30/25
- Patient global assessment (PtGA) (mm)
- 66/29/21/20
- BASDAI (mm)
- 58/26/21/19
- Bath AS Functional Index (BASFI) (mm)
- 46/20/16/16
- Health Assessment Questionnaire (HAQ)
- 0.8/0.4/0.2/0.2
- Pain reduced by ≈60% at 6 months
PRO response by TNFi treatment series
- Better PRO responses with a first TNFi compared to a second and third TNFi
Heterogeneity between registries
- Heterogeneity in baseline characteristics and outcomes between registries observed
Original publication
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment. J Rheumatol. Published 1 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →